Advanced Prostate Cancer

Home » Advanced Prostate Cancer

Evidence says less may be more when it comes to radiation for bone metastases

Advanced Prostate Cancer, Radiation / By / / 1 minute of reading

Patients enduring the excruciating pain of cancer that has spread to the bones are often given multiple doses of radiation. There is strong evidence, however, that one dose controls pain as effectively as 10 or more. In addition, one treatment is cheaper and far more convenient for patients who already have plenty on their minds. Read the Article.

Evidence says less may be more when it comes to radiation for bone metastases Read More »

VIDEO: Dr. Robert Hamilton, “Hormones, hormone therapy and prostate cancer”

Videos, Awareness Nights, Advanced Prostate Cancer / By / / 1 minute of reading

July 2013 Scotiabank Awareness Night “Hormones, hormone therapy and prostate cancer”       Dr. Robert J Hamilton MD, MPH, FRCSC  Surgical Oncologist, The Princess Margaret University Health Network  Assistant Professor, Dept. of Surgery (Urology), University of Toronto Testosterone and related hormones that together we call “androgens” play a role in every aspect of prostate cancer…from reducing chances of being diagnosed with prostate cancer, reducing progression of low risk prostate cancer, as an additive to radiation therapy, to suppressing growth in patients with advanced cancers. Dr. Hamilton presents the role of androgens and hormone therapy across the landscape of prostate

VIDEO: Dr. Robert Hamilton, “Hormones, hormone therapy and prostate cancer” Read More »

Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer—A Mechanistic Perspective

Advanced Prostate Cancer / By / / 1 minute of reading

Abstract Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. The mechanism of CRPC is not fully understood, but it may result from multiple pathways, including a loss or androgen receptor (AR) specificity and increased downstream signalling activity that provide multiple targets for therapeutic agents. For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. In Phase III clinical trials, these agents have

Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer—A Mechanistic Perspective Read More »

Breast cancer drug may ease prostate cancer side effects

Advanced Prostate Cancer, Hormone Side Effects / By / / 1 minute of reading

A widely used breast cancer drug may ease the side effects of prostate cancer treatment, according to a new German study. Scientists examined four studies involving men in Europe and North America undergoing therapy for prostate cancer, the common side effects of which are gynecomastia (breast enlargement) or breast pain. Read More.

Breast cancer drug may ease prostate cancer side effects Read More »

Survival Better with Continuous ADT

Advanced Prostate Cancer / By / / 1 minute of reading

Intermittent androgen deprivation therapy (ADT) has some quality-of-life (QOL) benefits for men with metastatic prostate cancer, but overall survival times are inferior to those seen with continuous ADT, according to the findings of a 17-year study (SWOG9346) presented at the American Society for Clinical Oncology 2012 annual meeting. Read More.

Survival Better with Continuous ADT Read More »

New Ways to Target Androgens in Prostate Cancer

Advanced Prostate Cancer / By / / 1 minute of reading

Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects. Read more.

New Ways to Target Androgens in Prostate Cancer Read More »

Scroll to Top